Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 352

  • Showing results for gahrton g. Search instead for Gharton G (1 item)
1.

Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma.

Gahrton G.

Lancet Haematol. 2017 Jun;4(6):e250-e251. doi: 10.1016/S2352-3026(17)30063-7. Epub 2017 May 15. No abstract available.

PMID:
28522109
2.

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.

Garderet L, Cook G, Auner HW, Bruno B, Lokhorst H, Perez-Simon JA, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schönland S, Kröger N.

Leuk Lymphoma. 2017 Apr;58(4):797-808. doi: 10.1080/10428194.2016.1228926. Epub 2016 Sep 21.

3.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N.

Leukemia. 2016 Oct;30(10):2047-2054. doi: 10.1038/leu.2016.101. Epub 2016 Apr 27.

4.

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.

Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, Arnold R, Bron D, Cordonnier C, Ernst P, Ferrant A, Frassoni F, Gahrton G, Richard C, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schattenberg A, Schmitz N, Torres-Gomez A, Zwaan F, Apperley J, Olavarria E, Kröger N; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation EBMT.

Ann Hematol. 2016 May;95(6):967-72. doi: 10.1007/s00277-016-2638-6. Epub 2016 Mar 19.

PMID:
26994010
5.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N.

Leuk Lymphoma. 2016;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6. Review.

6.

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG.

Leukemia. 2016 May;30(5):1005-17. doi: 10.1038/leu.2015.356. Epub 2015 Dec 29. Review.

PMID:
26710887
7.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E; American Society of Blood and Marrow Transplantation; European Society of Blood and Marrow Transplantation; Blood and Marrow Transplant Clinical Trials Network; International Myeloma Working Group Consensus Conference.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-51. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.

8.

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.

Duru AD, Sutlu T, Wallblom A, Uttervall K, Lund J, Stellan B, Gahrton G, Nahi H, Alici E.

PLoS One. 2015 Sep 17;10(9):e0138248. doi: 10.1371/journal.pone.0138248. eCollection 2015.

9.

A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.

Cardona ME, Simonson OE, Oprea II, Moreno PM, Silva-Lara MF, Mohamed AJ, Christensson B, Gahrton G, Dilber MS, Smith CI, Arteaga HJ.

Leuk Lymphoma. 2016;57(1):183-92. doi: 10.3109/10428194.2015.1043547. Epub 2015 Jun 18.

PMID:
25907616
10.

Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.

Grövdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, Pedersen PT, Hammerstrøm J, Laaksonen A, Bazia P, Terava V, Ollikainen H, Silvennoinen R, Putkonen M, Anttila P, Porkka K, Remes K.

Bone Marrow Transplant. 2015 Jun;50(6):808-12. doi: 10.1038/bmt.2015.39. Epub 2015 Apr 13.

PMID:
25867654
11.

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.

Sahebi F, Iacobelli S, Biezen AV, Volin L, Dreger P, Michallet M, Ljungman PT, de Witte T, Henseler A, Schaap NP, López-Corral L, Poire X, Passweg J, Hamljadi RM, Thomas SH, Schonland S, Gahrton G, Morris C, KrÖger N, Garderet L.

Bone Marrow Transplant. 2015 Jun;50(6):802-7. doi: 10.1038/bmt.2015.45. Epub 2015 Mar 23.

PMID:
25798673
12.

Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.

Nahi H, Våtsveen TK, Lund J, Heeg BM, Preiss B, Alici E, Møller MB, Wader KF, Møller HE, Grøseth LA, Østergaard B, Dai HY, Holmberg E, Gahrton G, Waage A, Abildgaard N.

Eur J Haematol. 2016 Jan;96(1):46-54. doi: 10.1111/ejh.12546. Epub 2015 Jun 29.

PMID:
25779478
13.

Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Morris C, Iacobelli S, Gahrton G, van Biezen A, Drake M, Garderet L, Potter M, Schattenberg AV, Cornelissen JJ, Hamladji RM, Martelli M, Petersen E, Rovira M, Bandini G, Kroger N, de Witte T.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1054-8. doi: 10.1016/j.bbmt.2015.02.012. Epub 2015 Feb 20.

14.

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.

Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee.

Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26.

PMID:
25621805
15.

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.

Uttervall K, Duru AD, Lund J, Liwing J, Gahrton G, Holmberg E, Aschan J, Alici E, Nahi H.

PLoS One. 2014 Jul 8;9(7):e101819. doi: 10.1371/journal.pone.0101819. eCollection 2014.

16.

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.

Liwing J, Uttervall K, Lund J, Aldrin A, Blimark C, Carlson K, Enestig J, Flogegård M, Forsberg K, Gruber A, Haglöf Kviele H, Johansson P, Lauri B, Mellqvist UH, Swedin A, Svensson M, Näsman P, Alici E, Gahrton G, Aschan J, Nahi H.

Br J Haematol. 2014 Mar;164(5):684-93. doi: 10.1111/bjh.12685. Epub 2013 Dec 9.

PMID:
24313224
17.

Allogeneic transplantation in multiple myeloma.

Gahrton G, Krishnan A.

Expert Rev Hematol. 2014 Feb;7(1):79-90. doi: 10.1586/17474086.2014.857270. Review.

PMID:
24224804
18.

Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.

Lund J, Uttervall K, Liwing J, Gahrton G, Alici E, Aschan J, Holmberg E, Nahi H.

Eur J Haematol. 2014 Jan;92(1):19-25. doi: 10.1111/ejh.12213. Epub 2013 Nov 15.

PMID:
24118547
19.

IMWG consensus on risk stratification in multiple myeloma.

Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. Review.

PMID:
23974982
20.

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.

Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N; Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2013 Nov;48(11):1395-400. doi: 10.1038/bmt.2013.73. Epub 2013 May 27.

PMID:
23708704

Supplemental Content

Loading ...
Support Center